We blend heart, science and ingenuity to profoundly change the trajectory of health for humanity. This aspiration includes a commitment to contribute to the evolution of healthcare and health innovation policy.
Janssen supports policies that serve the interests of patients, improve public health and promote access to medicines and innovations. We believe such policies should be created through ongoing dialogue and partnerships between governments, patients, civil society and scientific organisations and other stakeholders.
Tomorrow’s healthcare needs
The COVID-19 pandemic shone a spotlight on the sustainability and resiliency of health systems and the consequences of health emergencies for all of society. Healthcare systems and innovation policy both need to evolve to address today’s and tomorrow’s healthcare needs.
At Janssen, we believe these challenges present an opportunity to build on the crisis-born willingness to continue to create healthcare systems that reflect the value of health and wellbeing, support innovation, improve population health and strengthen global health security. We look forward to continuing to have a strategic dialogue with governments and the institutions of the European Union and other countries.
Collaboration and improving readiness for future health challenges
All stakeholders should continue the cooperation that was established during covid to prepare for future health challenges and health security crises.
We need further global cooperation on the development, testing, approval and production of vaccines and treatments. Policymakers and the industry should continue working together to ensure appropriate mechanisms are in place to accelerate the rapid deployment of effective interventions across the globe.
- Accelerated regulatory approvals for high unmet medical needs
- Acceptance of innovative clinical trial designs
- Dynamic regulatory assessments
- New pathways to personalised medicines and biomarker validation
- Greater regulatory harmonisation and reliance, especially in low- and middle-income countries
- Acceptance of real-world evidence in regulatory (and other) decision-making
“This pandemic has catalysed a spirit of collaboration and demonstrated what can be achieved when society comes together with one common goal”
Anouk De Vroey
Senior director, government affairs & policy EMEA, Johnson & Johnson
To watch the video on Intellectual Properties, please accept the cookies offered by this webpage.
We are committed to deliver the best care to patients in Europe in the fastest way possible. To do so, and to ensure the EU remains a leader for medical innovation, the intellectual property (IP) and incentives framework should be reinforced.
Anouk De Vroey, Head of Government Affairs & Policy EMEA set out to meet experts and explore as well as illustrate how IP facilitates development for different actors at many stages of the development process. Her conversations are captured in a series of videos produced for our Evolution of Healthcare Campaign in collaboration with POLITICO Studio.
In a first conversation Anouk discusses with Dirk De Smaele, Global Head Chemical Pharmaceutical Development & Supply. They explain how exactly IP contributes to providing options for patients and how it takes costs out of the health system.
Together with Prof. Dr. Thomas De Beer, professor in Process Analytical Technology at the Faculty of Pharmaceutical Sciences at Ghent University, Anouk sheds light on the vital role of IP for academic research and how it unlocks the ability for universities and institutes to collaborate as well as to reach patients through scaling of discoveries and new technologies.
The adoption of telemedicine across Europe has been rapid in recent years. Remote consultations and monitoring have provided an alternative to hospital visits, showing that digital options have the potential to free up resources in healthcare systems, and enable patient-centric solutions that people can receive in their own homes.
Health data collection is key for real-time disease diagnosis and tracking, epidemiological research or treatment discovery. We need to standardise health data as findable, accessible, interoperable and reusable, and, more than ever, create a European Health Data Space based on a federated network, while safeguarding privacy.
Continued digitalisation has the potential to lead to accelerated adoption of early diagnosis, enhanced screening programmes and advancing personalised care.
Supporting value-based healthcare
Methods are needed to define and agree on Key Performance Indicators (KPIs) to assess and track healthcare systems’ performance to improve patient and population health.
We believe value-based healthcare approaches can help ensure better population health outcomes and improved patient experience, while at the same time promoting sustainability by making better use of available resources.
The use of real-world data (RWD), from sources such as electronic health records, genomic information (information about a patient's DNA) and patient-derived data via apps, on a vast scale, may help improve decisions and consequently populations’ health.
In many countries, Health Technology Assessment processes and methodologies have a wide array of issues causing delays in patient access to innovative therapies. In a European context this is creating inequality in patient access. We need reforms in HTA methods to better reflect the value of these technologies.Read more about value-based healthcare Read more about how we work with patients
 Portnoy J, et al. Telemedicine in the Era of COVID-19. J Allergy Clin Immunol Pract. 2020;8(5):1489-1491.
 Barrett, M, et al. Artificial intelligence supported patient self-care in chronic heart failure: a paradigm shift from reactive to predictive, preventive and personalised care. EPMA Journal 2019;10:445–464.
 Akehurst, R.L., et al. Variation in Health Technology Assessment and Reimbursement Processes in Europe. Value in health. 2017;20(1):67-76.